Constellation Brands invests $4bn in Canada’s Canopy Growth
The Canada-based medical marijuana company, Canopy Growth, has announced a deal with the owner of Corona beer, Constellation Brands, that will see the US firm invest $4bn into Canada’s biggest producer of cannabis, BBC News reports.
The deal between the two global companies will become the largest investment in the industry to date.
Canopy will aim to broaden its business reach following the investment which will see it expand “in almost 30 countries that are pursuing a federally permissible medical cannabis programme.”
The Canadian company currently manufactures cannabis-based oils and soft gel caps, in addition with other products.
- Pieridae Energy set to launch $10bn Goldboro LNG project next month
- Innergrex Renewable Energy sees 37% growth in its revenue for second quarter
- Ensign Energy Services launches $947mn takeover bid for Trinidad Drilling
With the fresh injection of funds, Canopy will increase its selection of products to include edible bars, pre-rolled items and inhalers.
The firm also hopes to make a cannabinoid-based medicine that will offer a more secure alternative to treat anxiety, pain, sleeplessness and psoriasis.
Canopy's chief executive, Bruce Linton, on an investment call said: “This [deal] marks the end of the warm-up in our sector... it's fully go-time.”
Following news of the agreement, it was revealed that Canopy’s Toronto-listed stock rose 30%.
The two companies have collaborated previously when in 2017, Constellation invested $200mn in Canopy to offer a non-alcoholic cannabis-based beverage.
- Canadian cities have highest number of sustainable hotelsSustainability
- Canadian VC market has strongest first quarter on recordCorporate Finance
- How autism can help close Canada’s talent gap – DeloitteSustainability
- Deloitte: Top 10 fastest-growing tech companies in CanadaTechnology & AI